Quantcast

PhotoMedex to Present at Rodman & Renshaw 10TH Annual Healthcare Conference

November 4, 2008

PhotoMedex, Inc. (NASDAQ:PHMD), will participate in the Rodman & Renshaw 10th Annual Healthcare Conference being held from November 10-12, 2008 at the New York Palace Hotel in New York. The Company’s presentation is scheduled to begin at 4:30 p.m. Eastern Time on November 11, 2008. Representing PhotoMedex will be Jeffrey O’Donnell, president and chief executive officer, and Dennis McGrath, chief financial officer and vice president of finance.

The presentation will be webcast live on the PhotoMedex website at www.photomedex.com in the Investor Information section. An archived replay will be available on the site for 90 days.

The conference will feature presentations from more than 400 public and privately held emerging growth healthcare companies presenting data on an array of therapeutic topics including oncology, cardiovascular disease, central nervous system disorders, infectious diseases and medical device technology. Details regarding the conference can be obtained at www.rodmanandrenshaw.com.

About PhotoMedex

PhotoMedex offers a wide range of products and services across multiple specialty areas, including dermatology, urology, gynecology, orthopedics and other surgical specialties. PhotoMedex is a leader in the development, manufacturing and marketing of medical laser products and services. PhotoMedex also develops and markets products based on its patented, clinically proven Copper Peptide technology for skin health, hair care and wound care. PhotoMedex sells directly to dermatologists, plastic and cosmetic surgeons, spas and salons and through licenses with strategic partners into the consumer market, including a long-term worldwide license agreement with Neutrogena(R), a Johnson & Johnson company. ProCyte brands include Neova(R), Ti-Silc(R), VitalCopper(R), Simple Solutions(R) and AquaSante(R).

Safe Harbor Statement

Some portions of the conference call, particularly those describing PhotoMedex’ strategies, operating expense reductions and business plans and the other proposed transactions described in this press release, will contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While PhotoMedex is working to achieve those goals, actual results could differ materially from those projected in the forward-looking statements as a result of a number of factors, including continued increase in XTRAC procedures performed, difficulties in marketing its products and services, need for capital, competition from other companies, risks relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on strategic partners, the closing of the proposed Photo Therapeutics acquisition, and the related financing from Perseus, L.L.C. (the “Proposed Financing”) and the benefits and risks of this proposed acquisition and related financing, and other factors, any of which could have an adverse effect on the business plans of PhotoMedex, its reputation in the industry or its results. In light of significant uncertainties inherent in forward-looking statements included herein and in the conference call, the inclusion of such information in the conference call should not be regarded as a representation by PhotoMedex or its subsidiaries that the forward-looking statements will be achieved. For further details and a discussion of these and other risks and uncertainties, please see our annual report on 2007 Annual Report on Form 10-K, filed with the SEC on March 17, 2008, as amended by the Company’s annual report on Form 10-K/A, and our other period reports which are on file with the SEC. We undertake no obligation to publicly update any forward- looking statement, either as a result of new information, future events or otherwise.




comments powered by Disqus